Monday, November 3, 2014


The heart is linked to the soul for a reason: we couldn’t be happy or healthy without it! According to the American Heart Association, 34 percent of women and 52 percent of men have significant plaque buildup in their arteries (AHA, 2012). According to the American Heart Association, 47 million Americans now have metabolic syndrome. The syndrome afflicts 40% of people in their sixties and seventies. That number is expected to rise along with our aging population. The media plays a large role in advertising and gives people the sense that the only way to maintain healthy cholesterol levels is with pharmaceutical medicine. Most cholesterol is produced in the liver by the HMG-CoA reductase gene. Statin drugs work by blocking HMG-CoA, but they can often block too much. This leads to serious side effects because our body needs a minimum level of cholesterol for proper cellular function. Statin cholesterol-lowering drugs are among the most widely prescribed drugs on the market, bringing in $20 billion a year. They are a top profit-maker for the pharmaceutical industry, in part due to relentless and highly successful direct-to-consumer advertising campaigns. One in four Americans over the age of 45 now takes statins, typically for the primary prevention of heart attacks and strokes. Acceptance of novel mainstream therapies is not always advisable and an objective review found statins decrease energy and fitness, and increase fatigue and sleep problems. They also found that statins may increase the risk of muscle aches and pains, kidney and liver problems, bleeding in the brain, and type 2 diabetes.
Reliv International’s LunaRich® products, said Dr. Alfredo Galvez, “are the only nutritional products on the market that have a similar mechanism of action to that of statin drugs.” He explained that lunasin, a naturally occurring soy peptide—and the bioactive ingredient in LunaRich — reduces the expression of the HMG-CoA reductase gene through a patented epigenetic mechanism of action. “Lunasin binds to the histone H3 tail and inhibits H3-lysine 14 acetylation by the PCAF enzyme. HMG-CoA reductase is the rate-limiting enzyme for cholesterol biosynthesis and the enzyme that statin drugs inactivate. Although affecting the enzyme, lunasin differs from statins by reducing only the expression of HMGCoA reductase, not competitively inactivating the enzyme as statins do. This means that functional HMG-CoA reductase enzymes remain after lunasin consumption, although in lesser amounts, which in time leads to reduced LDL cholesterol levels. However, unlike statins with numerous side effects, including increased diabetes risk, muscle weakness and fatty liver disease, lunasin does not have side effects.”

Reliv RCN #  173198904

Post a Comment